UBC Acquires Gigamoto Technology Partners
The recent acquisition of Gigamoto Technology Partners (W. Conshohocken, PA) expands United BioSource Corporation's (Bethesda, MD) leadership in drug safety, the company says. The purchase is UBC's second of the year and provides the company with several risk management programs, including the largest and longest running FDA-mandated program: iPLEDGE, an interactive computer-based distribution center that monitors pregnancy in women on Accutane.
“Managing drug safety for increasingly complex drugs and biologicals requires world class scientific expertise, strong operations, and demands state of the art technology,” said Ethan Leder, Chief Executive Officer of United Biosource. “The acquisition of Gigamoto enhances and accelerates our technology platform to include more top-notch FDA approved technology solutions for complex post-approval programs."
The full press release is available here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
